Wire · regulatory
FDA's Generative AI Discussion Paper Signals a Break from the Past in Terminology, But ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 September 2026 · Fusion42 review
The FDA's discussion paper on generative AI-enabled medical devices signals potential shifts in terminology and regulatory approach, focusing on a competency-based evaluation model and revisiting risk assessment frameworks while inviting stakeholder feedback by October 19, 2026.
This Wire brief sits within Fusion42's coverage of Medtech, and 19 sources have reported it between 18 Aug 2026 and 18 Sep 2026.
◆ ◆ The Wire takeaway
You must prepare for a major rewrite in FDA compliance if you build generative AI medical devices. Engage deeply with the FDA’s questions by October 19 to shape a regulator process that could rapidly change market access and product design.
◆ Coverage
19 sources · first reported 18 Aug 2026 · latest 18 Sep 2026
◆ Related on Wire
◆ Topics